A large portfolio of previously validated biomarkers are readily available for us on client studies


For confidential advice on your specific project, please feel free to contact us. 


Propath offers its clients an extensive portfolio of biomarker methods previously validated by Propath covering a range of indications. Established IHC methods from routine proliferation markers to immuno-oncology markers are available immediately for clinical study samples or for transfer to alternative species.    

Rapid tissue screening studies for any of the following validated methods are available at Propath:

Functional Category
IHC Marker
Ki67, BrdU, Acetyl-Histone H3, PCNA
Apoptosis and DNA damage
Cleaved Caspase-3, RAD-51, γ-H2A.X
Immune cell markers
CD3, CD4, CD47, CD8, CD20, CD56, CD25, CD68, CD163, CD83
PD-L1, MHC-1
PD-1, FoxP3, F4/80, LY-75, CD80
Tissue markers
Vimentin, pan Cytokeratin,
CK19, WT1, CD31, CD71,
Insulin, Collagen IV, GFAP, Iba-1, Podocin
Her2, p53, p63, ß-catenin, Cyclin D1, Muc-1
Additional markers
Acetyl-α-Tubulin, FGFR2, NPY1R, SULT1, Loricrin, VMAT2, ß-Lactoglobulin, Adenovirus, Alpha-2u-globulin, FVIII, USP30